MatsukiyoCocokara & Co. (TYO: 3088)
Japan
· Delayed Price · Currency is JPY
2,257.50
-1.00 (-0.04%)
Jan 20, 2025, 3:30 PM JST
MatsukiyoCocokara & Co. Revenue
MatsukiyoCocokara & Co. had revenue of 265.98B JPY in the quarter ending September 30, 2024, with 2.48% growth. This brings the company's revenue in the last twelve months to 1.04T, up 4.68% year-over-year. In the fiscal year ending March 31, 2024, MatsukiyoCocokara & Co. had annual revenue of 1.02T with 7.49% growth.
Revenue (ttm)
1,040.49B
Revenue Growth
+4.68%
P/S Ratio
0.90
Revenue / Employee
77.82M
Employees
13,371
Market Cap
914.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,022.53B | 71.28B | 7.49% |
Mar 31, 2023 | 951.25B | 221.28B | 30.31% |
Mar 31, 2022 | 729.97B | 173.06B | 31.08% |
Mar 31, 2021 | 556.91B | -33.69B | -5.70% |
Mar 31, 2020 | 590.59B | 14.60B | 2.54% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,142.35B |
Daiichi Sankyo Company | 1,758.07B |
HOYA Corporation | 812.74B |
Takeda Pharmaceutical Company | 4,546.08B |
Otsuka Holdings | 2,269.56B |
Terumo | 986.67B |
Astellas Pharma | 1,772.16B |
Olympus | 973.60B |